Please enable Javascript
David F. McDermott, MD
Articles by David F. McDermott, MD
Expanding Treatment Horizons: Novel Approaches in RCC and Non-Clear Cell Disease
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
View More
Multidisciplinary Approaches to Managing IRAEs in RCC
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
View More
From Infusion to Injection: The Promise of Subcutaneous Nivolumab
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
View More
The Role of RCC Second-Line Therapy in Frontline Decision-Making: Does the Approach Matter?
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
View More
COSMIC-313 and the Future of Triplet Therapy in RCC: Efficacy, Toxicity, and Biomarkers
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
View More
Advancing Precision Medicine in RCC: The Role of Biomarkers in Treatment Decisions
Karine Tawagi, MD
Renal Cell Carcinoma
|
February 26, 2025
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
View More
Uromigos Live 2024 Front-Line Therapy in Papillary RCC Part 3: What Data is Forthcoming in Papillary RCC?
Brian Rini, MD, FASCO
Renal Cell Carcinoma
|
October 30, 2024
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
View More
Uromigos Live 2024 Front-Line Therapy in Papillary RCC Part 2: Major Data in Front-Line Papillary RCC
Brian Rini, MD, FASCO
Renal Cell Carcinoma
|
October 30, 2024
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
View More
Uromigos Live 2024 Front-Line Therapy in Papillary RCC Part 1: SUNNIFORECAST Discussion
Brian Rini, MD, FASCO
Renal Cell Carcinoma
|
October 30, 2024
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 4: What About CTLA-4-Based Salvage After IO in RCC?
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 30, 2024
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 3: IO Therapy After Adjuvant Pembrolizumab?
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 30, 2024
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 2: Do We Need a Post-Adjuvant Pembrolizumab Study?
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 29, 2024
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
View More
Uromigos Live 2024 RCC IO Rechallenge Part 1: CONTACT-03, TiNivo-2 Study Results and Implications
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 29, 2024
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
View More
Adjuvant Treatments and Systemic Therapy for nccRCC
Daniel Joyce, MD
nccRCC
|
October 19, 2024
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
View More
IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment
Daniel Joyce, MD
nccRCC
|
October 19, 2024
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
View More
Nephrectomy Versus Systemic Therapy and Risk Stratification in Papillary, Non-Papillary nccRCC
Daniel Joyce, MD
nccRCC
|
October 15, 2024
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
View More
IO/TKI and PD-L1 Approaches, Trials in nccRCC
Daniel Joyce, MD
nccRCC
|
October 15, 2024
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
View More
Management of Papillary Metastatic nccRCC
Daniel Joyce, MD
nccRCC
|
October 15, 2024
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
View More
Front-Line Therapy in Papillary Renal Cancer: Live Session From The Uromigos Live & Unplugged 2024
Brian Rini, MD, FASCO
Renal Cell Carcinoma
|
October 2, 2024
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View More
IO Rechallenge: Live Session From The Uromigos Live & Unplugged 2024
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 2, 2024
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
View More
Load More